ArticleThe Journal of experimental medicine2005
Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period.
Article in The Journal of experimental medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 234 citations in OpenAlex.
- CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.Science translational medicine · 2012Trial
- Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function.Journal of immunology (Baltimore, Md. : 1950) · 2012Trial
- In vivo expansion of naïve CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administration.PloS one · 2012Trial
- In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients.The Journal of clinical investigation · 2005Trial
- Understanding Immune Dynamics in Liver Transplant Through Mathematical Modeling.Bulletin of mathematical biology · 2025Article
- Association of Immune Cells, Inflammatory Cytokines, and Lung Cancer: A Mediating Mendelian Randomization Study.Mediators of inflammation · 2025Article
- The absolute number of circulating Treg cells is reduced in difficult-to-treat RA patients and is ameliorated by low-dose IL-2.Frontiers in immunology · 2025Article
- Review
- IL-2-based approaches to Treg enhancement.Clinical and experimental immunology · 2023Review
- Review
- IL-2 and IL-15 drive intrathymic development of distinct periphery-seeding CD4Frontiers in immunology · 2022Article
- Efficient IL-2R signaling differentially affects the stability, function, and composition of the regulatory T-cell pool.Cellular & molecular immunology · 2021Article
- Type 1 Diabetes and Autoimmune Thyroid Disease-The Genetic Link.Frontiers in endocrinology · 2021Review
- TCR Repertoires of Thymic Conventional and Regulatory T Cells: Identification and Characterization of Both Unique and Shared TCR Sequences.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Immunomodulation Followed by Antigen-Specific TDiabetes · 2020Article
- Role of Regulatory T Cells in Regulating Fetal-Maternal Immune Tolerance in Healthy Pregnancies and Reproductive Diseases.Frontiers in immunology · 2020Review
- Intrahepatic TFrontiers in pharmacology · 2020Review
- The Thymus in Chagas Disease: Molecular Interactions Involved in Abnormal T-Cell Migration and Differentiation.Frontiers in immunology · 2020Review
- Article
- Low-dose interleukin-2 alleviates dextran sodium sulfate-induced colitis in mice by recovering intestinal integrity and inhibiting AKT-dependent pathways.Theranostics · 2020Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Although many aspects of CD4(+)CD25(+) T regulatory (T(reg)) cell development remain largely unknown, signaling through the IL-2R represents one feature for the production of T(reg) cells. Therefore, the present study was undertaken to further define early developmental steps in the production of T(reg) cells, including a more precise view on the role of interleukin (IL)-2 in this process. After adoptive transfer of wild-type T(reg) cells into neonatal IL-2Rbeta(-/-) mice, only a small fraction of donor T(reg) cells selectively seeded the lymph node (LN). These donor T(reg) cells underwent rapid and extensive IL-2-dependent proliferation, followed by subsequent trafficking to the spleen. Thus, IL-2 is essential for T(reg) cell proliferation in neonatal LN. The number and distribution of T(reg) cells in the periphery of normal neonatal mice closely paralleled that seen for IL-2Rbeta(-/-) mice that received T(reg) cells. However, for normal neonates, blockade of IL-2 decreased T(reg) cells in both the thymus and LN. Therefore, two steps of T(reg) cell development depend upon IL-2 in neonatal mice, thymus production, and subsequent expansion in the LN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.